GlobeNewswire Inc | Nov 1, 2021 07:00AM EDT

November 01, 2021

Arecor Therapeutics plc(Arecor or the Group)

ARECOR ANNOUNCES AN EXCLUSIVE FORMULATION STUDY COLLABORATION WITHA LEADING GLOBAL MEDICAL PRODUCTSCOMPANY TO DEVELOP A STABLE READY TO ADMINISTERPRODUCT

Cambridge, UK, 1 November 2021: Arecor Therapeutics plc (AIM: AREC), the biopharmaceutical group advancing todays therapies to enable healthier lives, today announces that it has signed an exclusive formulation study collaboration with a leading global medical products company.

Under the terms of the agreement, Arecor will use its proprietary formulation technology platform, Arestat, to develop a differentiated, stable, liquid drug product, for intravenous administration in two concentrations, that is Ready-to-Administer (RTA). The new liquid formulation of the product supports safe medication practices and operational efficiency by eliminating the need for reconstitution. The partner will fund the development work and has the option to acquire the rights to the new proprietary formulation and associated Intellectual Property under a technology licensing model to further develop and commercialise the product.

Sarah Howell, Chief Executive Officer of Arecor, said"We are very pleased to announce this new partnership today, our fourth in the past six months, showcasing our commercial strategyto drive growth through our portfolio of collaborations across leading pharmaceutical, medical products and biotech companies. This collaboration further demonstrates the strength of our proprietary technology platform, Arestatin developing ready-to-administer (RTA) medicines, which are becoming increasingly important to enable fast, safe and effective treatment of patients.

This announcement contains inside information for the purposes of Article 7 of Regulation (EU) 596/2014 (MAR)

-ENDS-

For more information, please contact:

Arecor Therapeutics plc www.arecor.comDr Sarah Howell, Chief Executive Officer Tel: +44 (0) 1223 426060 Email: info@arecor.com Susan Lowther, Chief Financial Officer Tel: +44 (0) 1223 426060 Email: info@arecor.com Mo Noonan, Communications Tel: +44 (0) 7876 444977 Email: mo.noonan@arecor.com Panmure Gordon (UK) Limited (NOMAD andBroker) Tel: +44 (0) 20 7886 2500Freddy Crossley, Emma Earl (CorporateFinance)Rupert Dearden (Corporate Broking) Consilium Strategic Communications Chris Gardner, David Daley, Angela Gray Tel: +44 (0) 20 3709 5700 Email: arecor@consilium-comms.com

Notes to Editors

About Arecor Arecor Therapeutics plc is a globally focused biopharmaceutical company transforming patient care by bringing innovative medicines to market through the enhancement of existing therapeutic products. By applying our innovative proprietary formulation technology platform, Arestat, we are developing an internal portfolio of proprietary products in diabetes and other indications, as well as working with leading pharmaceutical and biotechnology companies to deliver enhanced formulations of their therapeutic products. The Arestat platform is supported by an extensive patent portfolio.

For further details please see our website, www.arecor.com